ePrints

A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients.

Lookup NU author(s): Dr Paul Mackin, Anthony Waton, Helen Watkinson, Dr Peter GallagherORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The relationship between antipsychotic use and cardiovascular morbidity and mortality is controversial. There is a lack of long-term prospective studies investigating changes in cardiometabolic risk in patients treated with antipsychotic drugs. We report data from a 4-year prospective study. Patients (89) underwent detailed metabolic and cardiovascular risk assessment at 4-years which included anthropometric assessment, blood pressure, lipid profile, and an oral glucose tolerance test. We used the homeostatic model assessment to determine insulin resistance, and calculated 10-year cardiovascular risk scores. Mean age of subjects was 44.7 (+/- 11.5) years, and 52% were male. The prevalence of type 2 diabetes was 8%, and 38.4% fulfilled diagnostic criteria for the metabolic syndrome. With the exception of increased central adiposity over the 4-year follow-up period (p < 0.001), other cardiometabolic parameters were generally unchanged. There was a high prevalence of dyslipidaemia, but only 16.9% were prescribed lipid-lowering treatment. Commencing lipid-lowering therapy was associated with a reduction in cardiovascular risk score (OR 7.9, 95% CI = 1.3 to 48.7; p = 0.02). Patients established on longer-term antipsychotic treatment show less dramatic metabolic changes than those occurring in the early stages of treatment, but have a high burden of cardiovascular risk. Lipid-lowering therapy is associated with a significant reduction in cardiovascular risk. (C) 2010 Elsevier Masson SAS. All rights reserved.

Publication metadata

Author(s): Mackin P, Waton T, Watkinson HM, Gallagher P

Publication type: Article

Publication status: Published

Journal: European Psychiatry

Year: 2012

Volume: 27

Issue: 1

Pages: 50-55

Print publication date: 30/10/2010

ISSN (print): 0924-9338

ISSN (electronic): 1778-3585

Publisher: Elsevier Masson

URL: http://dx.doi.org/10.1016/j.eurpsy.2010.08.011

DOI: 10.1016/j.eurpsy.2010.08.011

PubMed id: 21036552

Altmetrics

Share